Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
BMC Neurology|October 22, 2011
Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaireOscar Fernández, Victoria Fernández, Karine Baumstarck-Barrau, et al.
Brain : a Journal of Neurology|April 29, 2022
Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilanceHisakatsu Ito, Edita Navratilova, Barbora Vagnerova, et al.
Molecular Nutrition & Food Research|May 20, 2021
Safety and Efficacy of a Beverage Containing Lupine Protein Hydrolysates on the Immune, Oxidative and Lipid Status in Healthy Subjects: An Intervention Study (the Lupine-1 Trial)Ivan Cruz-Chamorro, Nuria Álvarez-Sánchez, Ana Isabel Álvarez-Ríos, et al.
International Journal of Cardiology|December 14, 2020
Contemporary trends in surgical rheumatic valve disease in a Caribbean nationNicola Pradegan, Juan R León-Wyss, José R Iribarren, et al.
The Journal of Clinical Investigation|April 17, 2025
B cells shape naïve CD8 T cell programmingCameron Manes, Miguel Guerrero Moreno, Jennifer Cimons, et al.
Clinical Chemistry and Laboratory Medicine|December 4, 2024
Point-of-care testing improves care timeliness in the emergency department. A multicenter randomized clinical trial (study POCTUR)Antonio Leon-Justel, Carmen Navarro Bustos, Jose Angel Noval-Padillo, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
<i>Lupinus angustifolius</i> Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE<sup>-/-</sup> MiceGuillermo Santos-Sánchez, Ivan Cruz-Chamorro, Ana Isabel Álvarez-Ríos, et al.
Plos One|May 17, 2018
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility studyOscar Fernández, Guillermo Izquierdo, Victoria Fernández, et al.
CNS Drugs|February 18, 2026
Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1)Ignacio Bejarano, Silvia Jiménez-Jorge, María Ángeles Lobo-Acosta, et al.
Immunohorizons|March 14, 2024
SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple SclerosisRyan M Baxter, Berenice Cabrera-Martinez, Tusharkanti Ghosh, et al.
Pageof 9